Article Details
Retrieved on: 2020-12-22 15:11:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
And, to be fair, Roche's faricimab did not miss exactly in its two head-to-head trials versus the leading diabetic macular oedema therapy, Regeneron's ...
Article found on: www.evaluate.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here